Loading...
Loading...
PGEN| Name | Value |
|---|---|
| Revenues | 1.2M |
| Cost of Revenue | 2.6M |
| Gross Profit | -1.3M |
| Operating Expense | 22.1M |
| Operating I/L | -23.4M |
| Other Income/Expense | 0.8M |
| Interest Income | 0.9M |
| Pretax | -33.4M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -33.1M |
Precigen, Inc. is a leading developer of gene and cellular therapies, offering disease-modifying therapeutics, genetically engineered swine for regenerative medicine, and reproductive technologies. The company's UltraVector platform utilizes advanced DNA construction technologies to design genetic components, while its mbIL15 gene enhances immune cell function. Precigen also provides gene switch systems, kill switches for cell therapy elimination, and tissue-specific promoters. Its product portfolio includes the UltraCAR-T platform for cancer treatment, AdenoVerse Immunotherapy, and ActoBiotics platform for mucosal protein delivery. The company generates revenue through collaboration and license agreements with various biotech firms.
